In support of this, inhibition of PPARγ by antagonists ameliorates high-fat diet (HFD)-induced obesity and impairments of glucose and lipid homeostasis [8, 11]. This evidence concerns the gene PPARG and obesity due to melanocortin 4 receptor deficiency.